Octreotide therapy in two children with intractable postoperative chylothorax

Abstract Postoperative chylothorax is sometimes difficult to be managed either by conventional therapies or by surgery. Herein, we report the experience of octreotide therapy for intractable postoperative chylothorax in two children (one was severe tetralogy of Fallot received Blalock–Taussing shunt...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cardiology Vol. 146; no. 3; pp. e63 - e65
Main Authors Hung, Wen-Pin, Wang, Jieh-Neng, Chang, Hok-Keong, Wu, Jing-Ming
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ireland Ltd 03.02.2011
Subjects
Cardiovascular
Chylothorax
Chylothorax - drug therapy
Congenital heart disease
Female
Humans
Infant
Infant, Newborn
Octreotide
Octreotide - therapeutic use
Postoperative
Postoperative Complications - drug therapy
Somatostatin
Somatostatin - analogs & derivatives
Somatostatin - therapeutic use
Postoperative
Octreotide
Congenital heart disease
Somatostatin
Chylothorax
Online AccessGet full text

Cover

More Information
Summary:Abstract Postoperative chylothorax is sometimes difficult to be managed either by conventional therapies or by surgery. Herein, we report the experience of octreotide therapy for intractable postoperative chylothorax in two children (one was severe tetralogy of Fallot received Blalock–Taussing shunt, and the other was a single ventricle received bi-directional Glenn shunt) and review the literature on octreotide efficacy.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 23
ObjectType-Report-3
ObjectType-Review-2
ObjectType-Case Study-4
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2008.12.210